Vous avez cherché: hyperlactataemia (Anglais - Suédois)

hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
hypertriglyceridemi, hyperkolesterolemi, insulinresistens, hyperglykemi och hyperlaktatemi se avsnitt 4. 4).

reports of fatal hepatic failure as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactataemia/lactic acidosis have been reported with use of ribavirin.
rapporter om dödlig leversvikt liksom perifer neuropati, pankreatit och symtomatisk hyperlaktatemi/mjölksyraacidos har rapporterats vid användning av ribavirin.

treatment with nucleoside analogues must be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
behandling med nukleosidanaloger ska utsättas vid symtomatisk hyperlaktatemi och metabolisk acidos/ laktacidos, progressiv hepatomegali eller snabbt stigande aminotransferasnivåer.

treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
behandling med nukleosidanaloger skall utsättas vid symtomatisk hyperlaktatemi och metabolisk acidos/ laktacidos, progressiv hepatomegali eller snabbt stigande aminotransferasnivåer.

the main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia).
de biverkningar som i huvudsak rapporterats är hematologiska rubbningar (anemi, neutropeni) och metabola rubbningar (hyperlaktatemi, hyperlipasemi).

11 combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
antiretroviral kombinationsbehandling har associerats med metaboliska störningar såsom hypertriglyceridemi, hyperkolesterolemi, insulinresistens, hyperglykemi och hyperlaktatemi (se avsnitt 4. 4).

lipids, lipodystrophy and metabolic abnormalities: combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin-resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
antiretroviral kombinationsterapi har associerats med metabola avvikelser som hypertriglyceridemi, hyperkolesterolemi, insulinresistens, hyperglykemi och hyperlaktatemi (se avsnitt 4. 4).